Visit Pfizer Medical

This site is intended for U.S. healthcare professionals.

Search

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

AboutCommitment to the GH communityIndications & DosingAdultsChildren DevicesPenPen presentationHow to use the Pen videoMiniQuickMiniQuick presentationHow to use the MiniQuick videoSupport and ServicesMaterialsVideosPatient Support and Savings
Prescribing InformationIndications Patient Site
The Pfizer Bridge Program®The Pfizer Bridge Program®Support for your GENOTROPIN patients throughout treatment

Our dedicated Patient Care Consultants (PCCs) are there to help support your patients. See some of the available Pfizer Bridge Program resources below.

Patient services
Benefit verification
Prior authorization assistance*
Appeals assistance*
Copay assistance†
Specialty pharmacy setup
Reauthorization and insurance changes

 

Benefit verificationCopay assistance
Prior authorization assistance*Specialty pharmacy setup
Appeals assistance*Reauthorization and insurance changes
Device training education and patient resources

Device training and patient resources

Scroll left to view table
The GENOTROPIN Starter KitDevice Support Hotline
Device training education with an experienced nurse
The GENOTROPIN Starter Kit
Device training education with an experienced nurse
Device Support Hotline
ReferencesOnce a Patient Enrollment Form has been submitted, PCCs can work with your patient to review either the prior authorization process and/or the reason for the denial. Once a prior authorization and/or appeal is submitted by the HCP, they can follow up with the payer on behalf of the patient and track the process until a final outcome is determined.For eligible patients.
Scroll left to view table
PCCs are available at 1-800-645-1280
GENOTROPIN Copay Program

We are committed to helping with out-of-pocket costs for patients through the GENOTROPIN Copay Program. See terms and conditions below.

ReferencesEligibility required. Annual savings up to $800-$1,500. State and federal beneficiaries not eligible. Terms and conditions apply; see below.ReferencesDependent on individual insurance plan restrictions. Additional requirements may apply.GENOTROPIN COPAY PROGRAM TERMS AND CONDITIONS

By using this offer for the GENOTROPIN Copay Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Eligible patients with commercial prescription drug insurance coverage for GENOTROPIN may pay as little [$0] per prescription fill. Patient out of pocket expense will vary. The value of this offer is limited to annual benefit of [$800-$1,500]. Once a patient reaches the annual maximum benefit, patient is responsible for paying the remaining monthly out of pocket costs.
  • Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patients must have private insurance. Offer is not valid for cash paying patients.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the GENOTROPIN Copay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the GENOTROPIN Copay Card as may be required. You should not use the GENOTROPIN Copay Card if your insurer or health plan prohibits use of manufacturer copay cards.
  • This copay card is not valid where prohibited by law.
  • The benefit under the GENOTROPIN Copay Program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Third party payers, pharmacy benefit managers, or the agents of either are prohibited from assisting patients with enrolling in the GENOTROPIN Copay Program.
  • Copay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “copay maximizer” programs).
  • Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or copay maximizer programs based on the availability of support under the GENOTROPIN Copay Program and/or exclude the financial assistance provided under the offer GENOTROPIN Copay Program from counting towards patient deductibles or out-of-pocket cost limitations.
  • Patients subject to an accumulator adjustment or copay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or copay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
  • Copay card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer at www.pfizerbridgecopay.com.
  • This copay card is not health insurance.
  • Offer good only in the U.S. (excluding Puerto Rico, the U.S. Virgin Islands, and Guam).
  • Copay card is limited to 1 per person during this offering period and is not transferable.
  • A copay card may not be redeemed more than once per 30 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  • Offer expires 12/31/[2026].
  • For questions regarding the offer, please call 1-[800-645-1280], visit www.genotropin.com, or write GENOTROPIN Copay Program, 430 Mountain Avenue, Suite 105, New Providence, NJ 07974
Updated Pfizer Bridge Program provider portal Discover the support programs available to your patients  Visit PfizerBridgeProgram.com to:
  • Help patients enroll in the Pfizer Bridge Program
  • Conduct electronic Benefit Verifications
  • Prepare and submit electronic Prior Authorization requests
  • Provide e-signatures for GENOTROPIN prescriptions
  • Track patient's status and receive notifications
  • Access digital forms and resources
Devices PBP Services Brochure

Find out more about the Pfizer Bridge Program here

Find out more Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-GEN-USA-1461
INDICATIONS

Indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (GH).

Indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing (see CONTRAINDICATIONS).

Indicated for the treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years.

Indicated for the treatment of growth failure associated with Turner syndrome (TS).

Indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone­deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Indicated for growth hormone replacement therapy in adults with growth hormone deficiency (GHD) of either childhood- or adult-onset etiology. GHD should be confirmed as appropriate.

Please see full Prescribing Information for Genotropin.
Important Safety Information CONTRAINDICATIONSGenotropin is contraindicated in patients with:
  • Acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure
  • Prader-Willi syndrome in children who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
  • Active malignancy
  • Hypersensitivity to somatropin or any of its excipients
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Pediatric patients with closed epiphyses
WARNINGS AND PRECAUTIONS
Acute Critical Illness: Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin. The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. The potential benefit of treatment continuation with somatropin in patients having acute critical illnesses should be weighed against the potential risk.
Prader-Willi Syndrome in Children: Fatalities have been reported after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin. If during treatment with somatropin, patients show signs of upper airway obstruction (including onset of or increased snoring) and/or new onset sleep apnea, treatment should be interrupted. All patients with Prader-Willi syndrome treated with somatropin should also have effective weight control and be monitored for signs of respiratory infection, which should be diagnosed as early as possible and treated aggressively.Neoplasms: In childhood cancer survivors who were treated with radiation to the brain/head for their first neoplasm and who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor all patients with a history of GHD secondary to an intracranial neoplasm routinely while on therapy. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies. Monitor for development of neoplasms. Monitor patients on somatropin therapy carefully for increased growth, or potential malignant changes, of preexisting nevi.Impaired Glucose Tolerance and Diabetes Mellitus: Treatment may decrease insulin sensitivity, particularly at higher doses. New-onset Type 2 diabetes mellitus has been reported. Monitor glucose levels periodically, especially in those with risk factors for diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin therapy. The doses of antihyperglycemic drugs may require adjustment when somatropin therapy is instituted.Intracranial Hypertension (IH): has been reported in patients treated with somatropin, usually within the first 8 weeks of treatment initiation. Perform fundoscopic examination before initiating treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating somatropin. Temporarily discontinue Genotropin in patients with evidence of IH. If IH is confirmed, restart Genotropin at a lower dose after IH signs and symptoms have resolved. Patients with Turner syndrome and Prader-Willi syndrome may be at increased risk.Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported. Inform patients and caregivers of the risk and that prompt medical attention should be sought if an allergic reaction occurs.Fluid Retention: may occur in adults. Clinical manifestations are usually transient and dose dependent.Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for pituitary hormone deficiency(s) may be at risk for reduced serum cortisol levels and/or unmasking of central hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of somatropin treatment. Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to somatropin, particularly in children. Patients with Turner syndrome have an inherently increased risk of developing autoimmune thyroid disease and primary hypothyroidism. Central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment. Monitor thyroid function periodically and appropriately initiate or adjust thyroid hormone replacement therapy.Slipped Capital Femoral Epiphyses in Pediatric Patients: May occur more frequently in patients with endocrine disorders or in patients undergoing rapid growth and lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients with the onset of a limp or complaints of hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly.Progression of Preexisting Scoliosis in Pediatric Patients: can occur in patients who experience rapid growth. Monitor patients with a history of scoliosis for progression of scoliosis.Otitis Media and Cardiovascular Disorders in Turner Syndrome: Patients with Turner syndrome should be evaluated carefully for otitis media and other ear disorders and cardiovascular disorders. Somatropin treatment may increase the occurrence of otitis media in these patients.Lipoatrophy: Tissue atrophy may result when somatropin is administered at the same site over a long period of time. Rotate injection sites to reduce this risk.Laboratory Tests: Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone, and IGF-1 may increase during therapy.Pancreatitis: Cases have been reported in children and adults receiving treatment. The risk may be greater in children compared with adults and girls who have Turner syndrome than other somatropin-treated children. Consider pancreatitis in patients who develop persistent severe abdominal pain.ADVERSE REACTIONS
Other common somatropin-related adverse reactions include injection site reactions/rashes and lipoatrophy and headaches.
DRUG INTERACTIONS
11 β-Hydroxysteroid Dehydrogenase Type 1:
Introduction of somatropin treatment may result in inhibition of 11βHSD-1 and reduced serum cortisol concentrations.
Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment: Adjust glucocorticoid replacement dosing in children receiving glucocorticoid treatment to avoid both hypoadrenalism and an inhibitory effect on growth.Cytochrome P450-Metabolized Drugs: Genotropin may alter the clearance. Monitor carefully if used with Genotropin.Oral Estrogen: Larger doses of Genotropin may be required.Insulin and/or Other Hypoglycemic Agents: Dose adjustment of insulin or hypoglycemic agent may be required.IndicationsGenotropin® (somatropin) is indicated for pediatric patients for the treatment of:
  • growth failure due to an inadequate secretion of endogenous growth hormone.
  • growth failure due to Prader-Willi syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing.
  • growth failure in children born small for gestational age who fail to manifest catch-up growth by age 2 years.
  • growth failure associated with Turner syndrome.
  • idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.
Genotropin is indicated for replacement of endogenous growth hormone in adults with either adult or childhood onset growth hormone deficiency. 
GHD should be confirmed as appropriate.